CliffBio
biologic

Adcetris

brentuximab vedotin

Loss of exclusivityAugust 2023projected — 12-year biologic exclusivity estimate
CompanySeagen →See this company's full patent-cliff portfolio

Drug detail

Brand nameAdcetris
Active ingredientbrentuximab vedotin
Strength50MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2011
Marketing statusRx

More from Seagen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Adcetris patent cliff — loss of exclusivity August 2023 | CliffBio